Shares of Smith & Nephew plc (NYSE:SNN – Get Free Report) have earned an average recommendation of “Moderate Buy” from the six ratings firms that are covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company.
SNN has been the subject of several recent analyst reports. StockNews.com upgraded shares of Smith & Nephew from a “buy” rating to a “strong-buy” rating in a research report on Monday, August 5th. Deutsche Bank Aktiengesellschaft assumed coverage on Smith & Nephew in a report on Wednesday, July 24th. They set a “buy” rating for the company. Finally, UBS Group upgraded Smith & Nephew from a “neutral” rating to a “buy” rating in a research report on Wednesday, June 5th.
Get Our Latest Stock Report on SNN
Hedge Funds Weigh In On Smith & Nephew
Smith & Nephew Stock Performance
NYSE:SNN opened at $30.80 on Friday. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.51 and a quick ratio of 1.11. Smith & Nephew has a fifty-two week low of $21.52 and a fifty-two week high of $31.72. The company has a 50 day simple moving average of $30.25 and a two-hundred day simple moving average of $27.16.
Smith & Nephew Increases Dividend
The business also recently declared a semi-annual dividend, which will be paid on Friday, November 8th. Shareholders of record on Friday, October 4th will be issued a $0.288 dividend. This represents a yield of 2.4%. This is a boost from Smith & Nephew’s previous semi-annual dividend of $0.24. The ex-dividend date is Friday, October 4th.
About Smith & Nephew
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.
Recommended Stories
- Five stocks we like better than Smith & Nephew
- Best Stocks Under $10.00
- Rocket Lab Stock Soars: Should Investors Chase the Rally?
- Utilities Stocks Explained – How and Why to Invest in Utilities
- KB Home Slips After Earnings: What’s Next for Homebuilders?
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Micron Stock Soars as AI Demand Fuels Big Q4 Earnings Beat
Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.